Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 29blinatumomab 19Vincristine 16Specimen Handling 13Methotrexate 13Dexamethasone 13fludarabine 12Prednisone 11Cytarabine 11Biopsy 11Doxorubicin 9Asparaginase 9Rituximab 8Mercaptopurine 8Inotuzumab Ozogamicin 8merphos 7Spinal Puncture 7N,N-dicyclohexyl-isoborneol-10-sulfonamide 7Magnetic Resonance Spectroscopy 7venetoclax 6prednylidene 6dexamethasone acetate 6dexamethasone 21-phosphate 6deltacortene 6azathiopurine 6auricularum 6Etoposide 6Daunorubicin 6Calcium Dobesilate 6pegaspargase 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Burkitt Lymphoma × brexucabtagene autoleucel × Clear all
NCT06144606 2026-03-31

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡